Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases


  • Cristian Lolli Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola - Italy
  • Antonio Verde Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Naples - Italy
  • Luca Degli Esposti Clicon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Bologna - Italy
  • Valentina Acciai IPSEN, Milan - Italy
  • Alessia Brigido IPSEN, Milan - Italy
  • Emanuela Proietti IPSEN, Milan - Italy
  • Sarah Scagliarini Department of Medical Oncology, AORN “A. Cardarelli”, Naples - Italy



Administrative databases, Cabozantinib, Real-world studies, Renal cell carcinoma, Treatment


Background: Cabozantinib use in everyday clinical practice for advanced or metastatic renal cell carcinoma (RCC) is relatively recent, and real-world data on treatment persistence, adherence and sequencing are still limited.

Methods: We conducted an analysis based on an integrated administrative database, covering around 6.9 million health-assisted Italian individuals, to explore the use of cabozantinib for RCC. Patients with at least one prescription for cabozantinib during 2017-2020 were searched. These were characterized during all available period (i.e. from 2010 onwards) before the index date and were observed after inclusion.

Results: A total of 113 patients treated with cabozantinib in second or subsequent line were included, and their demographic, clinical and treatment characteristics were described. About half of these RCC patients were aged >65 years (47.8%). Sixty patients (53.1%) were highly adherent to cabozantinib therapy, and the median cabozantinib treatment duration of use was 8.7 months (95% confidence interval: 5.8-11.1). During the first year of follow-up, the average total cost per patient was €32,508.

Conclusions: We described second or subsequent line cabozantinib treatment for RCC in a real-world setting and the economic burden of disease in Italy, taking advantage of large, integrated administrative databases.


Download data is not yet available.


Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon, France 2020: Accessed December 2023.

AIOM-AIRTUM. I numeri del cancro in Italia. Il Pensiero Scientifico Editore; 2021.

Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519-530. PMID:25449206 DOI:

Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79-87. PMID:32494314 DOI:

Powles T, Albiges L, Bex A, et al; ESMO Guidelines Committee. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511-1519. PMID:34597799 DOI:

Choueiri TK, Escudier B, Powles T, et al; METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814-1823. PMID:26406150 DOI:

Choueiri TK, Escudier B, Powles T, et al; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917-927. PMID:27279544 DOI:

Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591-597. PMID:28199818 DOI:

Choueiri TK, Powles T, Burotto M, et al; CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829-841. PMID:33657295 DOI:

Corrao G, Cantarutti A. Building reliable evidence from real-world data: needs, methods, cautiousness and recommendations. Pulm Pharmacol Ther. 2018;53:61-67. PMID:30253238 DOI:

Escudier B, de Zélicourt M, Bourouina R, Nevoret C, Thiery-Vuillemin A. Management and health resource use of patients with metastatic renal cell carcinoma treated with systemic therapy over 2014-2017 in France: a national real-world study. Clin Genitourin Cancer. 2022;20(6):533-542. PMID:36050262 DOI:

Hackshaw MD, Nagar SP, Parks DC, Miller LA. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Spec Pharm. 2014;20(6):603-610. PMID:24856598 DOI:

Ronconi G, Dondi L, Piccinni C, et al. Metastatic renal cancer: real-world evidence from a large Italian claims database. Glob Reg Health Technol Assess. 2021;8(1):1-7. PMID:36627861 DOI:

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481. DOI:

Albiges L, Fléchon A, Chevreau C, et al. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. Eur J Cancer. 2021;142:102-111. PMID:33253997 DOI:

Gan CL, Dudani S, Wells JC, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Med. 2021;10(4):1212-1221. PMID:33463028 DOI:

Maruzzo M, Pierantoni F, Bortolami A, et al. Real-world treatment with nivolumab or cabozantinib for metastatic renal cell carcinoma (mRCC) in the Veneto region of Italy: results of AMOUR study. Target Oncol. 2022;17(4):467-474. PMID:35751733 DOI:

Iacovelli R, Ciccarese C, Facchini G, et al. Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis. Target Oncol. 2020;15(4):495-501. PMID:32671807 DOI:

Navani V, Wells JC, Boyne DJ, et al. CABOSEQ: the effectiveness of cabozantinib in patients with treatment refractory advanced renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clin Genitourin Cancer. 2023 Feb;21(1):106.e1-106.e8. PMID:35945133 DOI:

Santoni M, Heng DY, Bracarda S, et al. Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: focus on sequences and prognostic factors. Cancers (Basel). 2019;12(1):84. PMID:31905816 DOI:

Shafrin J, Sullivan J, Chou JW, Neely MN, Doan JF, Maclean JR. The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma. Cancer Manag Res. 2017;9:731-739. PMID:29238223 DOI:

Italian Medicine Agency (AIFA). National report on medicines use in Italy – Year 2022 Rome, Italy. 2023. Accessed June 2024.

Edwards SJ, Wakefield V, Cain P, et al. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2018;22(6):1-278. PMID:29393024 DOI:

Stanisic S, Cicchetti A, Porta C, Procopio G, Berto P. Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. Glob Reg Health Technol Assess. 2018;5:1-9 . DOI:

Sarrazin MS, Rosenthal GE. Finding pure and simple truths with administrative data. JAMA. 2012;307(13):1433-1435. PMID:22474208 DOI:

Gini R, Schuemie MJ, Pasqua A, et al. Monitoring compliance with standards of care for chronic diseases using healthcare administrative databases in Italy: strengths and limitations. PLoS One. 2017;12(12):e0188377. PMID:29232365 DOI:

Trifirò G, Gini R, Barone-Adesi F, et al. The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand? Drug Saf. 2019;42(3):347-363. PMID:30269245 DOI:

Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26(3):155-159. PMID:22043406 DOI:

Additional Files



How to Cite

Lolli, C., Verde, A., Degli Esposti, L., Acciai, V., Brigido, A., Proietti, E., & Scagliarini, S. (2024). Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases. Global and Regional Health Technology Assessment, 11(1), 154–160.



Original Research Articles


Received 2023-12-13
Accepted 2024-06-06
Published 2024-07-03


Most read articles by the same author(s)